

ABSTRACT

The present invention concerns a method for the treatment of inflammatory arthritis, and in particular rheumatoid arthritis, by administering to the subject specific low dosages of N6- (3-iodobenzyl)-adenosine- 5'-N-methyl-uronamide (IB-MECA) and 2-chloro-N6- (3-iodobenzyl)-adenosine- 5'-N-methyl-uronamide
5 (CL-IB-MECA).